Zobrazeno 1 - 10
of 1 453
pro vyhledávání: '"C. Monneret"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
K. Wünscher
Publikováno v:
Starch - Stärke. 41:325-325
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5c43ed69370a85bae22e5768b9b10214
https://doi.org/10.1002/star.19890410817
https://doi.org/10.1002/star.19890410817
Autor:
C. MONNERET
Publikováno v:
Médecine et Armées Vol. 45 No.1 ISBN: 9782813004994
La naissance de la chimiothérapie des cancers date de la fin des années 1940, cinq ans après la fin de la Seconde Guerre mondiale. Deux mille bombes chargées d’ypérite sont entreposées dans les cales d’un navire des forces alliées, le John
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0e8b380fe9add3a449af9f95babd188b
https://doi.org/10.17184/eac.7456
https://doi.org/10.17184/eac.7456
Autor:
C. Monneret
Publikováno v:
Annales Pharmaceutiques Françaises. 72:229-237
Among the new molecular entities approved by the EMEA and the FDA in 2012, four have caught our attention for their significant contribution to the health of patient. First of all, among the notable 2012 approvals, is ivacaftor or Kalydeco®. This is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7fe919657c6f0390ceb608303fd21c8e
https://doi.org/10.1016/j.pharma.2014.03.001
https://doi.org/10.1016/j.pharma.2014.03.001
Autor:
C. Monneret
Publikováno v:
Annales Pharmaceutiques Françaises. 71:95-103
Among the 35 new molecular entities approved by the FDA in 2011, 17 were particularly notable for their significant contributions to the health of patients, including abiraterone acetate, vandetanib, belatacept and fidaxomicin. Thus, abiraterone acet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8dd0d2dfc91f33e12a2f0e266fb8fdb0
https://doi.org/10.1016/j.pharma.2013.01.004
https://doi.org/10.1016/j.pharma.2013.01.004
Autor:
C. Monneret
Publikováno v:
Annales Pharmaceutiques Françaises. 68:218-232
Resume Au milieu des annees 1990, avec le developpement de la chimie combinatoire et des criblages a haut debit, un moindre interet pour les produits naturels devint perceptible dans l’industrie pharmaceutique. Ce phenomene fut accentue par le fait
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5e4431cf3451593ba502b3ab9c4836cf
https://doi.org/10.1016/j.pharma.2010.04.004
https://doi.org/10.1016/j.pharma.2010.04.004
Autor:
C. Monneret
Publikováno v:
Annales Pharmaceutiques Françaises. 68:99-103
Bisphenol A (BPA) is used for the manufacture of polycarbonate plastics and epoxy resin. Since several years it has been reported that BPA belongs to the group of estrogenic xenobiotic or endocrine disruptors (EDC) which are non steroidal substances
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::136b9effa26cad7335a2221f62b07da2
https://doi.org/10.1016/j.pharma.2009.11.002
https://doi.org/10.1016/j.pharma.2009.11.002
Autor:
C. Monneret
Publikováno v:
Annales Pharmaceutiques Françaises. 67:154-157
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ce8e013f629693f3b5b725821d708a16
https://doi.org/10.1016/j.pharma.2008.12.003
https://doi.org/10.1016/j.pharma.2008.12.003